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Drug metabolism and androgen control therapy in 
prostatic cancer 
The drug metabolizing capacity during androgen control therapy was determined in 12 
patients with prostatic cancer, using plasma antipyrine half-life as an index. In general, drug 
metabolizing capacity seemed impaired; the disappearance rate of the test dmg decreased in 
8 of the patients. In 1 the half-life was unchanged, and in 3 there was shortening. The 
reS/dts suggest that many factors simultaneously affect the drug metabolizing enzymes, and the 
total effect may be stimulated in the face of therapy known to inhibit these enzymes. 
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The most common treatment for metasta-
sizing prostatic cancer during the past 30 
years has been orchiectomy combined with 
estrogen therapy, both of which have an 
arresting effect on this tumor.10-12 During 
the last years metabolie interactions during 
this therapy have been noticed to occur. 
Increased thromboembolic complications,20 
disturbances in liver function and jaun-
dice," 14. 17 changes in serum lipid frac-
tions lll and variability in results of oral 
glucose tests,15 and a variety of side effects4 
have been reported. 
Decreased activity of hepatic drug me-
tabolizing enzymes after castration have 
been reported in laboratory animals. 26 It is 
known that estrogens cause a similar de-
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crease in drug metabolism in test animals9 
and in human females using estrogen8 and 
oral contraceptives.6, 18 Recently low fast-
ing blood glucose levels have been reported 
in prostatic cancer patients receiving an-
drogen control therapy as weH as oral 
antidiabetic drugsY These may be caused 
in part by decreased metabolism of anti-
diabetic drugs as the result of drug inter-
action. 
The prostatic cancer patients are elderly 
men who often need drugs for other dis-
eases, so that it is important to know 
whether there are any changes in drug 
metabolism in these patients. This problem 
was examined using plasma antipyrine haIf-
life as index of drug metabolizing capacity 
before androgen therapy and while on it. 
Material and methods 
The subjects were 12 patients with 
histologically verif1ed prostatic cancer ad-
mitted consecutively during a 5 month 
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Fig. 1. Changes in plasma antipyrine half-life. 
period. In each patient the drug history, 
as weIl as sensitivity to drugs and chemi-
eals, was recorded (M. J. K.). All patients 
were castrated under general anesthesia 
with induction by thiopental and main-
tenance with oxygen and nitrous oxide. 
Alloferin (N-allyl-nortoxiferin) (not on U. S. 
market) was used as a muscle relaxant, 
and meperidine was used for pain relief. 
Estrogen therapy was started the day after 
castration, giving 500 mg diethylstilbestrol 
diphosphate intravenously daily for 10 
days. Other drug regimen were kept un-
ehanged during 11 days, exeept for occa-
sional administration of meperidine as an 
analgesie. 
Plasma antipyrine half-life was estimated 
in each patient before castration and on 
the tenth day after starting estrogen ther-
apy. The patients were given antipyrine 
(10 mg per kilogram ) in water in the 
moruing after an overnight fast. A blood 
sampIe for blank readings was obtained 
prior to the administration of the drug and 
was followed by sam pIes drawn at 3, 6, 9, 
and 12 hours, with precise sampling time 
being noted. The separated plasma was 
stored at -200 C. until analyzed in dupli-
cates by the method of Brodie and asso-
ciates.1 All sampIes from the same patients 
were carried out simultaneously. 
Blood sam pies for the liver function tests 
were drawn from the patients before castra-
tion and on the eleventh day after starting 
es trogen therapy. The concentrations of 
serum sodium, potassium, chloride, and 
creatinine were checked before castration 
and also several times during therapy. 
Statistical significance was determined by 
paired sampIe t test. 
Results 
Age, clinical findings of the patients on 
admission, bromsulphalein ( BSP) reten-
tion, and the half-life of antipyrine are 
listed in Table I. The mean value (± S.D.) 
for antipyrine in an patients was 7.7 ± 1.8 
hours before castration and 9.7 hours on 
the tenth day on estrogen. The difference 
is statistically significant (p < 0.05). In 8 
patients the half-life was significantly in-
creased (p < 0.01) from the average of 
7.5 hours to the average of 11.1 hours. In 
3 patients the half-life was decreased from 
the average of 9.0 hours to the average of 
7.0 hours (decrease not significant; p > 
0.05). In 1 patient the antipyrine half-life 
was unchanged. 
The BSP retention tests were elevated 
in 11 of the patients. The average retention 
was 3.7% (45 minutes test) before castra-
tion, and on the eleventh day it was 5.3 
(p < 0.05). In only 5 cases was the reten-
tion above the normal range (6.0%). The 
mean values for serum glutamic pyruvic 
transaminase, serum alkaline phosphatase, 
and serum bilirubin were, before castration, 
16.6 Wroblewsky units, 3.99 Bessey-Lowrey 
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Table I. Antipyrine half-life and BSP retention during androgen therapy 
Patient 
No. Age (yr.) Condition Metastases 
1 68 Poor + 
2 70 Good 
3 65 Poor + 
4 79 Good 
5 67 Poor + 
6 78 Good 
7 74 Good 
8 62 Poor 
9 81 Poor 
10 78 Good 
11 67 Poor 
12 70 Poor 
Mean 71.7 
S.D. 6.5 
p" 
0p values calculated by paired sampie t test. 
units, and 0.7 ing%; and after the es trogen 
treatment, 20.4 Wrbl units, 4.97 B-L units, 
and 0.8 mg%. These changes were not 
statistically significant. 
When the patients were grouped on the 
basis of their general condition into those 
with good and those with poor general 
condition, we found that the antipyrine 
half-life in the former group was 8.4 hours 
and in the latter group 7.2 hours before 
castration. The respective values after 
es trogen therapy were 10.4 hours and 8.7 
hours. The differences between the cor-
responding mean values in these two 
groups were not significant. No statistically 
significant correlation was found between 
a change in antipyrine half-life and that in 
any liver function test. 
Nine of the patients received other drugs 
for concurrent disease: 8 for urinary tract 
infections, 3 for coronary artery diseases, 
2 for congestive heart diseases, 3 for pain 
relief, and 1 for diabetes mellitus. The 
drugs were found not to interfere with the 
determination of antipyrine. 
None of the patients had any side effects 
from the antipyrine. 
Discussion 
Antipyrine is almost completely metab-
olized in the liver by hydroxylating en-
Antipyrine half-life (hr.) 
BSP-retention (%) 
Before I J Change Before I After After (%) 
3.5 7.2 6.0 10.0 +66 
12.0 12.7 11.0 9.0 -18 
5.4 7.2 7.0 9.0 +28 
4.9 5.8 8.0 11.0 +37 
1.5 2.6 5.0 12.0 +140 
1.8 2.2 7.0 12.0 +78 
1.6 2.2 7.0 10.0 +28 
1.6 3.6 6.0 6.0 ±O 
2.2 5.0 8.0 7.0 -12 
5.5 6.2 9.0 11.0 +22 
3.7 2.7 11.0 14.0 +27 
0.3 7.1 8.0 5.0 -37 
3.6 5.4 7.7 9.7 +11 
3.1 3.1 1.8 2.6 
0.05 0.05 
zymes. 2 In man, the metabolism of anti-
pyrine is under genetic control,23 but the 
activity of antipyrine hydroxylating en-
zymes can be enhanced or decreased by 
medicaments or environmental chemi-
cals.13• 23 The change in the half-life of 
plasma antipyrine therefore reflects hepatic 
antipyrine hydroxylating activity.23,25 Ac-
cording to our results, drug metabolism in 
patients with prostatic cancer is decreased 
during androgen therapy; there was a pro-
longation in the half time of the test drug. 
Compatible reports have been published in 
castrated animals,9, 26 in estrogen-pretreated 
animals, and in human females. 6, 8, 18 
Although little is known about the fac-
tors affecting drug metabolism,20 it may 
be assumed that drug-metabolizing en-
zymes are induced, by drugs as weIl as by 
other factors, in patients who have concur-
rent disease and are in paor condition. This 
assumption is supported by the observation 
that the change in antipyrine half-life was 
less marked in patients in poor general 
condition. The effect of diseases on drug 
metabolism has not yet been fully investi-
gated, but marked improvement in the 
liver function in patients has been reported 
after heart failure has been successfully 
treated. 21 
In the liver function tests, significant 
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changes were noted only in BSP retention. 
While no interrelationships were noted be-
tween the changes of the half-life of anti-
pyrine and that of BSP retention, we dem-
onstrated that the activity of antipyrine 
hydroxylating enzymes need not correlate 
with slight changes in the liver function 
tests. 
Therapy with estrogen may cause re-
tention of sodium and water,19 and surgery 
may have a similar effect.27 A slight in-
crease in the total body water was ob-
served while concentrations of serum 
electrolytes varied within a normal range. 0 
While the antipyrine half-lifes were indi-
vidually calculated from the postabsorption 
phase of the curve, it is probable that small 
changes in absorption and distribution of 
antipyrine had no significant effect on its 
metabolism.3,15 
Elderly people often have diseases that 
require many drugS.5, 22, 28 Our results em-
phasize the importance of individualized 
drug therapy for patients with prostatic 
cancer. 
°Unpublished observation. 
References 
1. Brodie, B. B., Axelrod, J., Soberman, R., and 
Levy, B. B.: The estimation of antipyrine in 
biological materials, J. Biol. Chem. 179:25-29, 
1949. 
2. Brodie, B. B., and Axelrod, J.: The fate of 
antipyrine in man, J. Pharmacol. Exp. Ther. 
98:97 -104, 1950. 
3. Buchler, D., and Warren, J. C.: Effects of 
estrogen on glucose tolerance, Am. J. Obstet. 
Gynecol. 95:479-483, 1966. 
4. Calabresi, P., and Parks, R. E.: Alkylating 
agents, antimetabolites, hormones, and other 
antiproliferative agents, in Goodman, L. S., and 
Gilman, A., editors: The pharmacological basis 
of therapeutics, ed. 4, New York, 1970, The 
Macmillan Company, pp. 1384-1385. 
5. Cluff, L. E., Thoronton, G. F., and Seidl, L. 
G.: Studies on the epidemiology of adverse 
drug reactions, J. A. M. A. 188:976-983, 1964. 
6. Crawford, J. S., and Rudofsky, S.: Some altera-
tions in the pattern of drug metabolism asso-
eiated with pregnancy, oral contraceptives, and 
the newly born, Br. J. Anaesth. 38:446-453, 
1966. 
7. Dahl, P., and Schmid, E.: Arzneimittelikterus 
Clinical Pharmacology 
and Therapeutics 
durch oestrogens beim Mann. Z., Gastro-
enterology 7: 183-185, 1969. 
8. Fahim, M. S., Hall, D. G., and Fahim, Z.: 
Urinary D-glucaric acid. An index of hepatic 
microsamal enzyme activity in human females, 
Am. J. Obstet. Gynecol. 105:124-126, 1969. 
9. Fletcher, H. P., Miya, T. S., and Bousquet, 
W. F.: Influence of estradiol on the disposition 
of chlorpromazine in the rat, J. Pharm. Sei. 
54: 1007-1009, 1965. 
10. Herbst, W. P.: The effects of estradiol 
dipropionate and diethylstilbestrol on malig-
nant prostatic tissue, Trans. Am. Assoe. Genito-
urin. Surg. 34:195-202, 1941. 
11. Huggins, C., and Hodges, C. V.: Studies on 
prostatic cancer. 1. The effect of castration, of 
estrogen and of androgen injection on serum 
phosphatases in metastatic carcinoma of the 
prostate, Cancer Res. 1 :293-298, 1941. 
12. Huggins, C., Stevens, R. E., and Hodges, C. 
V.: Studies on prostatic cancer: Effects of 
castration on advanced carcinoma of prostate 
gland, Arch. Surg. 43:209-233, 1941. 
13. Kolmodin, B., Azarnoff, D. L., and Sjöqvist, F.: 
Effect of environmental factors on drug me-
tabolism: Decreased plasma half-life of anti-
pyrine in workers exposed to chlorinated 
hydrocarbon insecticides, CLIN. PHARMACOL. 
THER. 10:638-642, 1969. 
14. Kontturi, M., and Sotaniemi, E.: Effect of 
estrogen on liver function of prostatic cancer 
patients, Br. Med. J. 2:204-205, 1969. 
15. Kontturi, M., and Sotaniemi, E.: Estrogen 
induced metabolie ehanges during treatment of 
prostatic cancer, Scand. J. Clin. Lab. Invest. 
25:45( suppl. 113), 1970. 
16. Kontturi, M., and Sotaniemi, E.: Effeet of 
estrogen on the serum eholesterol and triglycer-
ide levels of prostatic cancer patients, J. Urol. 
105:847-849, 1971. 
17. Kontturi, M., Sotaniemi, E., and Ahlquist, J.: 
Liver damage and estrogen therapy of prostatic 
cancer, Scand. J. Urol. Nephrol. 6:289-297, 
1972. 
18.0'Malley, K., Stevenson, I. H., and Crooks, J.: 
Impairment of human drug metabolism by oral 
contraceptive steroids, CLIN. PHARMACOL. 
THER. 13:552-557, 1972. 
19. Preedy, J., and Aitken, E.: The effect of 
estrogen on water and electrolyte metabolism. 
1. The normal, J. Clin. Invest. 35:423-429, 
1956. 
20. Prescott, L. F.: Drug metabolism and thera-
peutics, Scott. Med. J. 16:121-129, 1971. 
21. Richman, S. M., Delman, A. J., and Grob, D.: 
Alterations in indices of liver function in con-
gestive heart failure with particular referenee 
to serum enzymes, Am. J. Med. 30:211-225, 
1961. 
22. Sotaniemi, E., and Palva, I. P.: The use of 
Volurne 14 
Nurnber3 
polypharmaceutical drug therapy in a medical 
ward, Ann. Clin. Res. 4:158-164, 1972. 
23. Vesell, E. S., and Page, J. G.: Genetic control 
of the phenobarbital-induced shortening of 
plasma antipyrine half-lives in man, J. Clin. 
lnvest. 48:2202-2209, 1969. 
24. Vesell, E. S., Page, J. G., and Passananti, G. 
T.: Genetic and environmental factors affecting 
ethanol metabolism in man, CLIN. PHARMACOL. 
THER. 12:192-201, 1971. 
25. Veterans Administration Cooperative Urological 
Research Group: Treatment and survival of 
Androgens and drug metabolism 417 
patients with cancer of the prostate, Surg. 
Gynecol. Obstet. 124:1011-1017, 1967. 
26. Wada, F., Yoshida, M., and lsohashi, F.: 
Effects of adrenalectomy and castration on 
enzyme metabolizing drugs in mouse Iiver, J. 
Biochem. 71 :343-345, 1972. 
27. Waller, W. F., Watt, A., Morgan, H. G., and 
Parker, J.: Metabolism after surgery inthe 
elderly, Proc. Nutr. Soc. 30:172-179, 1971. 
28. Wade, 0.: Pattern of drug induced disease in 
the community, Br. Med. BuH. 26:240-244, 
1970. 
